As of 2026, BPC-157 has no completed, published human randomized controlled trials for musculoskeletal or wound-healing indications
By month 4, GI side effects fade into background noise for 85%+ of patients, leaving appetite suppression as the primary ongoing effect, which is the desired therapeutic response
Type 2 Diabetes Improved Glycemic Control : Cagrilintide reduces hemoglobin A1C by up to 2.2%, improves insulin sensitivity, and decreases glucagon levels, contributing to better glucose management ( 3 )
Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria
Deficiency is more common than you might think, especially in people with limited meat intake, digestive disorders, or high demands during pregnancy